Pregabalin (PGB) is a new antiepileptic drug (AED) which is a structural, non-functional analogue of gamma-aminobutyric acid. It acts at presynaptic calcium channels to modulate neurotransmitter release in the CNS. While the efficacy and tolerability of PGB have been demonstrated in several randomised controlled trials, few studies have addressed long-term outcome in large groups of patients. A cohort of patients attending a tertiary referral centre for epilepsy was identified as having started taking PGB. Patients' data were obtained through medical records. Of 402 patients included, 42% of patients were still taking PGB at last follow-up. The estimated 2.5-year retention rate was 32%. Males appeared more likely to continue on PGB therapy than females. The common adverse experiences (AEs) leading to withdrawal were CNS-related, psychiatric AEs and weight gain. Published retention rates for levetiracetam appear to be higher, and those for gabapentin lower, than the rates estimated for PGB.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eplepsyres.2009.08.001DOI Listing

Publication Analysis

Top Keywords

cohort patients
8
tertiary referral
8
referral centre
8
pgb
6
patients
5
long-term retention
4
retention pregabalin
4
pregabalin large
4
large cohort
4
patients epilepsy
4

Similar Publications

Introduction: Surgical site infection (SSI) after lower extremity (LE) bypass surgery is associated with longer length of stay, higher hospital cost, increased morbidity, and even graft loss. Silver impregnated dressings have been used by other surgical subspecialties to decrease SSI with reported success. The National Surgical Quality Improvement Program (NSQIP) published a national expected rate of 7.

View Article and Find Full Text PDF

Introduction: Access to rehabilitation services after a traumatic injury improves functional outcomes. No study has examined the association between injury intent, violent versus nonviolent, and receipt of rehabilitation services after injury.

Materials And Methods: We conducted a retrospective cohort study of injured adult patients admitted to our level I trauma center from January 1, 2014 to December 31, 2021.

View Article and Find Full Text PDF

Objective: To provide an updated synthesis on effects of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on weight, BMI, and waist circumference incorporating newer randomized controlled trials (RCTs), particularly in individuals with overweight or obesity.

Research Design And Methods: We systematically searched PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) for RCTs published from inception to 4 October 2024. The search was limited to RCTs evaluating the use of GLP-1 RAs for mean differences from baseline in weight, BMI, and waist circumference in adults with obesity or overweight with or without diabetes.

View Article and Find Full Text PDF

Is Area-Level Social Vulnerability Index Associated With Patient-Level Health-Related Social Needs in Hand Surgery?

J Am Acad Orthop Surg

January 2025

From the Department of Orthopaedic Surgery, Stanford University, Stanford, CA (Schultz), Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, PA (Zhuang), Department of Orthopaedic Surgery, University of California-San Francisco, San Francisco, CA (Shapiro), Department of Orthopaedic Surgery, VOICES Health Policy Research Center, Stanford University, Stanford, CA (Kamal).

Background: Social drivers of health (SDOH) are area-level, nonmedical factors that affect health outcomes. By contrast, health-related social needs (HRSNs) are individual patient reported and are being deployed in some payment models. SDOH are often used to broadly represent health disparities of communities through metrics, such as the Social Vulnerability Index (SVI); however, the association of area-level SVI to individual HRSNs has not been well studied in hand surgery, which has implications for addressing social risks to improve health and in quality measurement.

View Article and Find Full Text PDF

Although lymphoma and myeloma confer physical and psychological burden, data are limited regarding anxiety and depression symptoms in affected patients. We conducted a survey between 07/2021 and 09/2022 to characterize anxiety and depression in a cohort of adult patients, within six months of a lymphoma or myeloma diagnosis. Clinically significant anxiety and depression symptoms were defined as scores ≥8 on the corresponding subscales of the Hospital Anxiety and Depression Scale.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!